Mercer Global Advisors
IKT icon

Mercer Global Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Mercer Global Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1K Buy
+16,781
New +$30K ﹤0.01% 4533

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $140M AUM
SSC
Spruce Street Capital New York $510M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's IKT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 16,781 shares worth $34.1K. The stake represents ﹤0.01% of the portfolio and ranks #4533 among its holdings.

87 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Mercer Global Advisors held 16,781 shares of Inhibikase Therapeutics worth $34.1K as of Q2 2026.
  • Inhibikase Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4533 holding.
  • 87 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.